

3. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. *Curr Opin Chem Biol.* 2009;13:256–262.
4. Müller C. Folate-based radiotracers for PET imaging: update and perspectives. *Molecules.* 2013;18:5005–5031.
5. Siwowska K, Haller S, Bortoli F, et al. Preclinical comparison of albumin-binding radiofolates: impact of linker entities on the in vitro and in vivo properties. *Mol Pharm.* 2017;14:523–532.
6. Boss SD, Müller C, Siwowska K, et al. Reduced <sup>18</sup>F-folate conjugates as a new class of PET tracers for folate receptor imaging. *Bioconjug Chem.* 2018;29:1119–1130.
7. Ross TL, Müller C, Groehn V, Schibli R, Ametamey SM. A new <sup>18</sup>F-labeled folic acid derivative with improved properties for the PET imaging of folate receptor-positive tumors. *J Nucl Med.* 2010;51:1756–1762.
8. Juzeniene A, Tam TTT, Iani V, Moan J. 5-methyltetrahydrofolate can be photo-degraded by endogenous photosensitizers. *Free Radic Biol Med.* 2009;47:1199–1204.
9. Steindal AH, Juzeniene A, Johnsson A, Moan J. Photodegradation of 5-methyl-tetrahydrofolate: biophysical aspects. *Photochem Photobiol.* 2006;82:1651–1655.
10. Blair JA, Pearson AJ, Robb AJ. Autooxidation of 5-methyl-5,6,7,8-tetrahydro-folic acid. *J Chem Soc Perkin Trans 2.* 1975;6:18–21.
11. Betzel T, Müller C, Groehn V, et al. Radiosynthesis and preclinical evaluation of 3'-aza-2'-[<sup>18</sup>F]fluorofolic acid: a novel PET radiotracer for folate receptor targeting. *Bioconjug Chem.* 2013;24:205–214.
12. Wilson AA, Jin L, Garcia A, DaSilva JN, Houle S. An admonition when measuring the lipophilicity of radiotracers using counting techniques. *Appl Radiat Isot.* 2001;54:203–208.
13. Müller C, Mindt TL, de Jong M, Schibli R. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy. *Eur J Nucl Med Mol Imaging.* 2009;36:938–946.
14. Ladino CA, Chari, Ravi VJ, Bourret L, Kedersha NL, Goldmacher VS. Folate-maytansinoids: target-selective drugs of low molecular weight. *Int J Cancer.* 1997;73:859–864.
15. Zheng X-H, Jiang L-Y, Zhao L-T, Zhang Q-Y, Ding L. Simultaneous quantitation of folic acid and 5-methyltetrahydrofolic acid in human plasma by HPLC–MS/MS and its application to a pharmacokinetic study. *J Pharm Anal.* 2015;5:269–275.
16. Berova N, Di Bari L, Pescitelli G. Application of electronic circular dichroism in configurational and conformational analysis of organic compounds. *Chem Soc Rev.* 2007;36:914–931.
17. Petroselli G, Erra-Balsells R, Cabrerizo FM, et al. Photosensitization of 2'-deoxy-adenosine-5'-monophosphate by pterin. *Org Biomol Chem.* 2007;5:2792–2799.
18. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and anti-folates. *Biochem Pharmacol.* 1992;44:1898–1901.
19. Fowler B. The folate cycle and disease in humans. *Kidney Int Suppl.* 2001;78: S221–S229.

### Erratum

In “Characterization of 3 Novel Tau Radiopharmaceuticals, <sup>11</sup>C-RO-963, <sup>11</sup>C-RO-643, and <sup>18</sup>F-RO-948, in Healthy Controls and in Alzheimer Subjects,” by Wong et al. (*J Nucl Med.* 2018;59:1869–1876), the indicated affiliations for Susan Resnick and Esther Oh are incorrect. The correct affiliations should be *Susan Resnick<sup>6</sup>, Lab of Behavioral Neuroscience, NIH-NIA IRP, Baltimore, Maryland;* and *Esther Oh<sup>7</sup>, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.* In addition, affiliation 1 should read *Section of High Resolution Brain PET, Department of Radiology and Radiological Sciences, Division of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.* In the Key Words, “tau radiopharmaceuticals” was inadvertently left out of the list. Finally, the last name of one of the authors was misspelled. “Abhay Mogekar” should be “Abhay Moghekar.” We regret these errors.